Lakefront Biotherapeutics (LKFT) Other Operating Expenses (2016 - 2026)

Lakefront Biotherapeutics (LKFT) has 11 years of Other Operating Expenses data on file, last reported at $1.3 million in Q1 2026.

• Other Operating Expenses for Q1 2026 came in at $1.3 million, down 81.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.9 million (down 91.64% YoY), and the FY2025 annual result was $62.3 million, up 42.92% from the prior year.
• Other Operating Expenses eased to $1.3 million in Q1 2026 per LKFT's latest filing, from $5.7 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $60.1 million in Q4 2024 and troughed at -$32.7 million in Q3 2024.
• A 5-year average of $12.7 million and a median of $9.4 million in 2024 frame the typical range for Other Operating Expenses.
• On a YoY basis, Other Operating Expenses climbed as much as 329.36% in 2024 and fell as far as 337.56% in 2024.
• A 5-year view of Other Operating Expenses shows it stood at $6.8 million in 2022, then surged by 106.07% to $14.0 million in 2023, then jumped by 329.36% to $60.1 million in 2024, then tumbled by 90.56% to $5.7 million in 2025, then sank by 77.65% to $1.3 million in 2026.
• Business Quant data shows LKFT's Other Operating Expenses at $1.3 million in Q1 2026, $5.7 million in Q2 2025, and $6.9 million in Q1 2025.